MTOR and cancer: The results indicated that SLC2A1 may be linked to key cancer hallmarks, including the G2M checkpoint, glycolysis, the PI3K-AKT-mTOR pathway, and epithelial-mesenchymal transition (EMT) (Figure 2A).